Ann: Test Platform and COVID-19 Test receive CE Mark approval, page-669

if you read Anteotech's ann's and interviews it's possible to understand Anteo's future direction. imo..

"Operon has a manufacturing capacity of 8 million complete tests (test strip and cassettes assembly and packaging) per annum and a test strip production capacity of approximately 20 million lateral flow strips per annum. This capacity will provide AnteoTech with enough capacity to fulfil initial demand for the EuGeni ART"

so we will have 8m completed tests that will fill initial demand. the demand that is currently in Europe. the individual country trials in India and France have commenced more than 3 weeks ago. with Germany and the UK a little later.

we aren't interested in the small volume of tests currently used in Australia. as seen, as we have delayed our TGA submission (even though we have used the TGA's tester VIDRL do our initial trial) and concentrating on MDSAP which will make further CE and FDA and TGA approvals an easier route. this doesn't sound like a company that is scrambling to fill orders, but one that is confident initial demand is already there.

we have this from 3 weeks ago.

"Saliva use case on track for CE Mark update in June 2021."

I would imagine our UK trial already concluded and CE Mark update submitted and we are waiting for approval. any day or a couple of weeks?

when we have this approval we will have several sp drivers to follow.imo.

-results of our individual country trials, India, UK, Germany, France etc.
-contract from potential customers that already have our reader and test in their hands "as a precursor to purchasing"
-with timelines we should be close to a design freeze on our covid/flu test, allowing time for trial and FDA approval before US autumn and winter hit.
-signing cassette assembly partners to complete the extra 12m operon test strips and our future 12m in house
-still very interested in the UK TTP and airlines once approval is granted
-Anteotech second site leased and an automation partner signed


plenty to be announced, but as usual more patience is needed imo...... just as an exercise what would our sp be with only 8m tests sold at $15 - $20 ea or revenue of $120m - $160m. that will be an interesting quarterly !!!! all sp fluctuations to me, is just noise at the moment. DYOR etc...

ps. hoping to get another update on coll8 in the near future.